Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms

被引:1
作者
Hu, Huihui [1 ]
Zhao, Jin [1 ]
Yuan, Judong [1 ]
Zhang, Man [1 ,2 ,3 ]
机构
[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Clin Lab, 10 Tieyi Rd, Beijing 100038, Peoples R China
[2] Beijing Key Lab Urinary Cellular Mol Diagnost, Beijing, Peoples R China
[3] Peking Univ, Clin Lab Med, Sch Clin Med 9, Beijing 100038, Peoples R China
关键词
PD-1; Tim-3; Peritoneal neoplasms; Primary sites; Pathological types; Progression-free survival; Flow cytometry; T-CELL EXHAUSTION; NIVOLUMAB; CANCER; IMMUNOTHERAPY; BIOMARKERS; EXPRESSION; BLOCKADE;
D O I
10.1186/s12885-023-10752-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeProgrammed death-1 (PD-1) and T cell immunoglobulin and mucin-domain-containing molecule 3(Tim-3) may be used as the biomarkers for the therapy in patients with peritoneal neoplasms. In the current study, the differential percentages of peripheral PD-1 and Tim-3 are explored to investigate whether to associate with primary sites and pathological types of patients with peritoneal neoplasms or not. We also investigated the frequencies of PD-1 and Tim-3 on circulating Lymphocytes, CD3 + T cells, CD3 + CD4 + T cells and CD3 + CD8 + T cells if would correlate with the progression-free survival of peritoneal neoplasms patients.Methods115 patients with peritoneal neoplasms were recruited, subjected to multicolor flow cytometric analyses of the percentages of PD-1 and Tim-3 receptors of circulating Lymphocytes, CD3 + T cells, CD3 + CD4 + T cells and CD3 + CD8 + T cells. The peritoneal neoplasms patients were divided into primary group and secondary group depending on whether the tumor had primary focus and limited to peritoneal tumor or not. Then all the patients were regrouped by the pathological types of neoplasms (adenocarcinoma, mesothelioma, and pseudomyxoma). The secondary peritoneal neoplasms group was divided into the different primary site groups (colon, gastric, gynecology). This study also enrolled 38 cases of normal volunteers. The above markers were explored by flow cytometer, to find the differential levels in peritoneal neoplasms patients compared with normal group in peripheral blood.ResultsHigher levels of CD4 + T lymphocytes, CD8 + T lymphocytes, CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells, CD3 + CD4 + PD-1 + T cells, CD3 + CD8 + PD-1 + T cells and CD45 + Tim-3 + lymphocytes were found in peritoneal neoplasms group than normal control (the p value was respectively 0.004, 0.047, 0.046, 0.044, 0.014, 0.038 and 0.017). Compared with primary peritoneal neoplasms group, the percentages of CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells, and CD3 + CD4 + PD-1 + T cells were increased in the secondary peritoneal neoplasms group (the p value was respectively 0.010, 0.044, and 0.040), while PD-1 did not correlate with the primary sites in secondary group (P > 0.05). Tim-3 had no statistical differences in primary peritoneal neoplasms group compared with secondary group (p > 0.05), but CD45 + Tim-3+% lymphocytes, CD3 + Tim-3+%T cells, and CD3 + CD4 + Tim-3 + T cells were associated with different secondary sites of peritoneal neoplasms (p < 0.05). In the different pathological type groups, the percentages of CD45 + PD-1 + lymphocytes, CD3 + PD-1 + T cells presented the higher levels in adenocarcinoma group compared with mesothelioma group (p = 0.048, p = 0.045). The frequencies of CD45 + PD-1 + lymphocytes and CD3 + PD-1 + T cells in peripheral blood were associated with progression-free survival (PFS).ConclusionsOur work uncovers peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. Those findings might provide important assessment to predict peritoneal neoplasms patients' immunotherapy responses.
引用
收藏
页数:11
相关论文
共 30 条
  • [21] IMMUNOTHERAPY PD-1 says goodbye, TIM-3 says hello
    Romero, Diana
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (04) : 203 - 203
  • [22] Emerging Tim-3 functions in antimicrobial and tumor immunity
    Sakuishi, Kaori
    Jayaraman, Pushpa
    Behar, Samuel M.
    Anderson, Ana C.
    Kuchroo, Vijay K.
    [J]. TRENDS IN IMMUNOLOGY, 2011, 32 (08) : 345 - 349
  • [23] Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
    Sakuishi, Kaori
    Apetoh, Lionel
    Sullivan, Jenna M.
    Blazar, Bruce R.
    Kuchroo, Vijay K.
    Anderson, Ana C.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2010, 207 (10) : 2187 - 2194
  • [24] Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance
    Sánchez-Fueyo, A
    Tian, J
    Picarella, D
    Domenig, C
    Zheng, XX
    Sabatos, CA
    Manlongat, N
    Bender, O
    Kamradt, T
    Kuchroo, VK
    Gutiérrez-Ramos, JC
    Coyle, AJ
    Strom, TB
    [J]. NATURE IMMUNOLOGY, 2003, 4 (11) : 1093 - 1101
  • [25] Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
    Topalian, Suzanne L.
    Taube, Janis M.
    Anders, Robert A.
    Pardoll, Drew M.
    [J]. NATURE REVIEWS CANCER, 2016, 16 (05) : 275 - 287
  • [26] Tsoukalas N, 2019, J BUON, V24, P883
  • [27] PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
    Yaghoubi, Neda
    Soltani, Arash
    Ghazvini, Kiarash
    Hassanian, Seyed Mahdi
    Hashemy, Seyed Isaac
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2019, 110 : 312 - 318
  • [28] Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
    Yang, Riyao
    Sun, Linlin
    Li, Ching-Fei
    Wang, Yu-Han
    Yao, Jun
    Li, Hui
    Yan, Meisi
    Chang, Wei-Chao
    Hsu, Jung-Mao
    Cha, Jong-Ho
    Hsu, Jennifer L.
    Chou, Cheng-Wei
    Sun, Xian
    Deng, Yalan
    Chou, Chao-Kai
    Yu, Dihua
    Hung, Mien-Chie
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [29] Zhang Y, 2015, MEDICINEOL, V94, P515
  • [30] Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
    Zhou, Qing
    Munger, Meghan E.
    Veenstra, Rachelle G.
    Weigel, Brenda J.
    Hirashima, Mitsuomi
    Munn, David H.
    Murphy, William J.
    Azuma, Miyuki
    Anderson, Ana C.
    Kuchroo, Vijay K.
    Blazar, Bruce R.
    [J]. BLOOD, 2011, 117 (17) : 4501 - 4510